capabl
induc
elev
express
cellular
receptor
angiotensin
ii
receptor
blocker
angiotensinconvert
enzym
inhibitor
arbsacei
treatment
may
controversi
role
facilit
viru
infect
reduc
pathogen
inflamm
aim
evalu
correl
arbsacei
usag
pathogenesi
retrospect
singlecent
studi
patient
preexist
hypertens
hubei
provinci
hospit
tradit
chines
medicin
hphtcm
wuhan
januari
februari
retrospect
alloc
arbsacei
group
nonarbsacei
group
accord
antihypertens
medic
ageand
sexmatch
patient
without
hypertens
randomli
select
nonhypertens
control
addit
medic
histori
hypertens
patient
admit
hphtcm
novemb
decemb
outbreak
also
review
extern
comparison
epidemiolog
demograph
clinic
laboratori
data
collect
analyz
compar
group
frequenc
arbsacei
usag
hypertens
patient
without
compar
among
patient
hypertens
receiv
either
arbsacei
nonarbsacei
compar
blood
pressur
howev
arbsacei
group
significantli
lower
concentr
crp
procalcitonin
pct
furthermor
much
lower
proport
critic
patient
vs
lower
death
rate
vs
observ
arbsacei
group
nonarbsacei
group
although
differ
fail
reach
statist
signific
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
medrxiv
preprint
angiotensinconvert
enzym
cellular
receptor
facilit
infect
light
recent
investig
predict
receptor
bind
domain
rbd
spike
glycoprotein
sarscov
share
almost
ident
conform
bind
affin
rbd
estim
much
stronger
assess
comput
model
notion
later
confirm
biophys
analysi
inde
use
test
protein
cellular
entri
receptor
viru
infect
studi
use
hela
cell
express
human
decemb
novel
coronaviru
diseas
caus
sever
acut
respiratori
syndrom
coronaviru
emerg
wuhan
hubei
provinc
china
diseas
rapidli
spread
wuhan
area
march
case
report
countri
area
contin
current
crude
case
fatal
rate
cfr
thu
accumul
case
high
cfr
pose
great
challeng
public
health
accord
recent
report
patient
infect
diagnos
pneumonia
hospit
includ
sever
diseas
howev
underli
pathophysiolog
mechan
viru
caus
diseas
remain
unclear
sarscov
coronavirus
two
virus
share
ident
nucleotid
sequenc
earli
studi
establish
sarscov
use
retrospect
studi
compli
declar
helsinki
approv
hubei
provinci
hospit
tradit
chines
medicin
hphtcm
ethic
review
board
clinic
ethic
approv
hphtcm
respons
treatment
assign
wuhan
govern
patient
confirm
accord
guidelin
fifth
trial
version
chines
nation
health
commiss
admit
hphtcm
januari
februari
includ
initi
screen
patient
preexist
hypertens
retrospect
alloc
two
subgroup
arbsacei
nonarbsacei
group
accord
usag
antihypertens
drug
ageand
sexmatch
case
randomli
select
remain
patient
without
hypertens
nonhypertens
control
clinic
outcom
ie
discharg
mortal
length
stay
monitor
march
final
date
followup
addit
medic
histori
hypertens
patient
admit
hphtcm
novemb
decemb
outbreak
also
review
extern
comparison
written
inform
consent
waiv
ethic
commiss
hospit
emerg
infecti
diseas
medic
record
patient
analyz
research
team
hphtcm
diseas
onset
defin
date
symptom
notic
data
use
acei
arb
prior
admiss
hospit
stay
collect
inform
includ
demograph
data
medic
histori
exposur
histori
comorbid
symptom
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
sign
laboratori
find
treatment
measur
ie
antivir
therapi
corticosteroid
therapi
extract
electron
medic
record
record
standard
data
collect
form
data
review
train
team
physician
assess
diseas
statu
follow
guidelin
fifth
trial
version
chines
nation
health
commiss
mild
type
slight
clinic
symptom
imag
present
pneumonia
common
type
fever
respiratori
tract
symptom
imag
find
pneumonia
sever
type
follow
condit
respiratori
distress
respiratori
frequenc
timesminut
finger
oxygen
satur
rest
oxygen
index
pao
fio
mmhg
kpa
critic
type
follow
condit
respiratori
failur
requir
mechan
ventil
shock
combin
organ
failur
requir
intens
care
unit
care
treatment
laboratori
paramet
includ
complet
blood
count
creactiv
protein
crp
arteri
blood
ga
analysi
myocardi
injuri
marker
coagul
profil
serum
biochem
test
includ
renal
liver
function
lactat
dehydrogenas
procalcitonin
pct
btype
natriuret
peptid
bnp
measur
accord
manufactur
instruct
data
analysi
perform
use
spss
statist
packag
social
scienc
version
categor
variabl
report
absolut
rel
frequenc
compar
test
fisher
exact
test
continu
variabl
express
mean
sd
normal
distribut
median
interquartil
rang
iqr
compar
independ
group
test
mannwhitney
u
test
respect
p
consid
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
statist
signific
initi
screen
patient
alloc
two
group
hypertens
group
includ
patient
preexist
hypertens
nonhypertens
group
compris
ageand
sexmatch
patient
randomli
select
remain
patient
without
hypertens
figur
patient
hypertens
alloc
two
subgroup
base
usag
arbsacei
antihypertens
drug
arbsacei
subgroup
nonarbsacei
subgroup
figur
median
age
patient
two
subgroup
iqr
iqr
year
respect
major
differ
characterist
two
subgroup
except
higher
usag
antibiot
nonarbsacei
subgroup
baselin
characterist
shown
tabl
age
distribut
complic
ratio
hypertens
group
nonhypertens
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
compar
nonhypertens
control
patient
preexist
hypertens
lower
arteri
partial
pressur
oxygen
vs
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
tabl
retrospect
investig
knowledg
first
casecontrol
studi
aim
examin
correl
arbsacei
pathogenesi
infect
patient
preexist
hypertens
major
find
report
arbsacei
treatment
associ
reduc
inflammatori
respons
mitig
diseas
progress
patient
preexist
hypertens
compar
antihypertens
treatment
hypertens
lead
caus
mortal
global
adult
estim
hypertens
worldwid
sinc
emerg
infect
hypertens
frequent
observ
major
comorbid
patient
report
patient
admit
hphtcm
preexist
hypertens
incid
similar
report
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
discord
could
explain
age
differ
latter
two
studi
median
age
year
respect
compar
year
report
patient
hypertens
appear
higher
death
rate
frequent
seen
sever
case
also
examin
death
rate
incid
critic
case
cohort
compar
nonhypertens
control
patient
hypertens
higher
death
rate
differ
fail
reach
statist
signific
howev
find
patient
remain
hospit
significantli
longer
diseas
cours
patient
hypertens
without
vs
therefor
result
togeth
group
provid
ampl
evid
hypertens
critic
risk
factor
poor
clinic
outcom
patient
inde
notion
support
laboratori
test
result
patient
hypertens
much
lower
blood
oxygen
index
p
well
higher
blood
urea
alt
without
hypertens
mechan
hypertens
result
poor
clinic
outcom
remain
obscur
found
compar
nonhypertens
control
patient
hypertens
markedli
increas
level
inflammatori
hscrp
procalcitonin
suggest
dysregul
inflammatori
respons
might
contribut
fact
hypertens
wellknown
capac
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
stimul
adapt
respons
induc
elev
product
inflamm
cytokin
ii
effector
peptid
ra
respons
pathophysiolog
hypertens
also
demonstr
capabl
induc
product
multipl
anim
model
surprisingli
treatment
hypertens
patient
acei
arb
function
reduc
level
ii
increas
express
effect
downregul
product
inflammatori
cytokin
increas
level
inflammatori
cytokin
also
observ
patient
without
hypertens
coexist
ill
huang
et
al
report
plasma
concentr
cytokin
significantli
higher
icu
patient
nonicu
patient
infect
healthi
adult
comparison
found
higher
icu
patient
nonicu
patient
elev
concentr
also
demonstr
patient
sever
critic
diseas
compar
mild
common
ill
base
evid
multicent
random
control
trial
recent
regist
chines
clinic
trial
registri
evalu
efficaci
safeti
blockad
tocilizumab
treatment
mention
inhibit
dysregul
inflammatori
respons
repres
promis
therapeut
strategi
hypertens
patient
therefor
acei
arb
capabl
reduc
product
inflammatori
cytokin
potenti
candid
drug
treatment
patient
preexist
hypertens
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
suggest
sever
group
howev
clinic
evid
still
miss
report
found
patient
hypertens
treat
arbsacei
diagnos
infect
concentr
inflammatori
crp
procalcitonin
significantli
lower
compar
treat
nonarbsacei
arbsacei
treatment
also
result
lower
death
rate
less
critic
case
patient
find
concentr
arbsacei
group
significantli
differ
nonarbsacei
control
suggest
arbsacei
treatment
alon
might
effici
modul
product
cytokin
howev
combin
arbsacei
blockad
could
presum
synerg
effect
regul
elev
inflammatori
respons
patient
preexist
hypertens
could
test
futur
clinic
trial
arbsacei
treatment
report
increas
express
also
cellular
receptor
infect
arbsacei
treatment
pose
ad
risk
infect
studi
cohort
report
bind
approxim
higher
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
affin
bind
sarscov
find
togeth
fact
peopl
differ
race
differ
age
sex
suscept
infect
suggest
physiolog
express
may
alreadi
suffici
infect
upregul
might
increas
risk
arb
acei
antihyperhens
drug
discov
maintain
blood
pressur
thu
arbsacei
treatment
could
result
hypotens
healthi
subject
may
prevent
applic
patient
without
hypertens
altern
novel
therapeut
option
use
target
promis
treat
infect
without
affect
blood
pressur
studi
sever
limit
first
due
retrospect
natur
studi
fact
conduct
singl
hospit
interpret
find
might
limit
sampl
size
select
bia
also
realiz
addit
risk
factor
may
wellcontrol
despit
mani
confound
possibl
correct
nevertheless
far
know
largest
retrospect
cohort
studi
design
examin
usag
arbsacei
effect
patient
preexist
hypertens
second
sever
diseas
cours
ident
among
patient
result
difficulti
collect
laboratori
indic
time
point
therefor
select
extrem
valu
beyond
normal
rang
laboratori
indic
could
reflect
sever
condit
comparison
howev
strategi
might
still
caus
bias
present
laboratori
indic
third
express
inflammatori
factor
determin
studi
due
sampl
avail
limit
technic
resourc
hospit
limit
prevent
us
explor
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
mechan
arbsacei
regul
inflammatori
statu
patient
hypertens
evid
present
studi
support
use
arbsacei
antihypertens
drug
treat
patient
preexist
hypertens
larg
prospect
studi
requir
confirm
find
explor
mechan
arbsacei
regul
inflammatori
respons
prevent
diseas
progress
effort
might
eventu
lead
develop
novel
therapeut
agent
target
treat
nonhypertens
patient
without
affect
blood
pressur
declar
compet
interest
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
novelti
signific
hypertens
report
lead
coexist
ill
patient
patient
frequent
treat
arbsacei
control
blood
pressur
effect
arbsacei
pathogenesi
yet
defin
conduct
first
largest
case
seri
evalu
effect
arbsacei
pathogenesi
patient
preexist
hypertens
found
without
increas
risk
infect
arbsacei
outcompet
antihypertens
drug
contain
exagger
inflammatori
respons
curb
diseas
progress
patient
preexist
hypertens
result
support
use
arbsacei
antihypertens
drug
treat
patient
preexist
hypertens
larg
prospect
studi
requir
confirm
find
explor
mechan
arbsacei
regul
inflammatori
respons
prevent
diseas
progress
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
p
valu
test
mannwhitney
u
test
p
consid
statist
signific
bold
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
figur
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
figur
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
